SCHEMBL5530563

SCHEMBL5530563

CCN(CC)Cc1ccc(-n2cc(C(=O)O)c(=O)c3cc(F)c(N4CCN(c5ccc(F)cc5F)CC4)c(OC)c32)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
KDM4E B2RXH2 8/20 0.48
ALDH1A1 P00352 4/20 0.48
POLB P06746 3/20 0.48
HSP90AA1 P07900 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
TOP1 P11387 7/20 0.47
KCNH2 Q12809 3/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
CYP2C19 P33261 1/20 0.42
TDP1 Q9NUW8 3/20 0.41
PRKD3 O94806 1/20 0.41
ALOX15 P16050 1/20 0.41
OPRM1 P35372 1/20 0.41
CLK2 P49760 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
TOP2A P11388 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5528205 0.92 KDM4E (0.49) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5525034 0.92 TOP1 (0.51) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5525045 0.92 LMNA (0.47) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5524079 0.92 TOP1 (0.48) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5533362 0.90 TOP1 (0.47) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5525059 0.89 TOP1 (0.48) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5531755 0.88 TOP1 (0.47) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5535408 0.87 TOP1 (0.44) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5530215 0.87 TOP1 (0.44) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL5525086 0.87 TOP1 (0.46) LMNAKMT2AMEN1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213339-A1 Quinolone Carboxylic Acid Derivatives for Treatment of Hyperproliferative Conditions TP53, RB1, HRAS LMNA 1366/4885KMT2A 2389/4885MEN1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.